NCT01807598View on ClinicalTrials.gov

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Aggressive Systemic MastocytosisMast Cell LeukemiaSystemic Mastocytosis
Interventions
DRUG

Brentuximab vedotin

Trial Locations (2)

77030

MD Anderson Cancer Center, Houston

94305

Stanford University, School of Medicine, Stanford

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Jason Robert Gotlib

OTHER

NCT01807598 - Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | Biotech Hunter | Biotech Hunter